Journal
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
Volume 20, Issue 1, Pages 65-+Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cgh.2020.11.017
Keywords
Barrett's Esophagus; Esophageal Adenocarcinoma; Endoscopic Eradication Therapy; Endoscopic Mucosal Resection; Endoscopic Submucosal Dissection
Categories
Funding
- National Cancer Institute [CA 241162]
- FreemanFoundation
Ask authors/readers for more resources
Endoscopic submucosal dissection (ESD) achieves higher complete remission rates of dysplasia in Barrett's esophagus patients compared to cap-assisted endoscopic mucosal resection (cEMR), although rates of complete remission of intestinal metaplasia (CRIM) at 2 years and complication rates are similar between the two groups.
BACKGROUND & AIMS: Endoscopic resection is an important component of the endoscopic treatment of Barrett's esophagus (BE) with dysplasia and intramucosal adenocarcinoma. Endoscopic resection can be performed by cap-assisted endoscopic mucosal resection (cEMR) or endoscopic submucosal dissection (ESD). We compared the histologic outcomes of ESD vs cEMR, followed by ablation. METHODS: We queried a prospectively maintained database of all patients undergoing cEMR and ESD followed by ablation at our institution from January 2006 to March 2020 and abstracted relevant demographic and clinical data. Our primary outcomes included the rate of complete remission of dysplasia (CRD): absence of dysplasia on surveillance histology, and complete remission of intestinal metaplasia (CRIM): absence of intestinal metaplasia. Our secondary outcome included complication rates. RESULTS: We included 537 patients in the study: 456 underwent cEMR and 81 underwent ESD. The cumulative probabilities of CRD at 2 years were 75.8% and 85.6% in the cEMR and ESD groups, respectively (P < .01). Independent predictors of CRD were as follows: ESD (hazard ratio [HR], 2.38; P < .01) and shorter BE segment length (HR, 1.11; P < .01). The cumulative probabilities of CRIM at 2 years were 59.3% and 50.6% in the cEMR and ESD groups, respectively (P> .05). The only independent predictor of CRIM was a shorter BE segment (HR, 1.16; P < .01). CONCLUSIONS: BE patients with dysplasia or intramucosal adenocarcinoma undergoing ESD reach CRD at higher rates than those treated with cEMR, although CRIM rates at 2 years and complication rates were similar between the 2 groups.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available